118 related articles for article (PubMed ID: 2341526)
1. Determination of tauromustine and its demethylated metabolites in plasma and urine.
Polacek J; Gustafsson B; Brandin S; Ottersgård-Brorsson A
J Chromatogr; 1990 Mar; 526(1):151-7. PubMed ID: 2341526
[TBL] [Abstract][Full Text] [Related]
2. Determination of tauromustine, a nitrosourea-based antitumour agent, in plasma by high-performance liquid chromatography.
Polacek J; Gunnarsson PO; Brandin S
J Chromatogr; 1988 Mar; 425(2):424-8. PubMed ID: 3372655
[No Abstract] [Full Text] [Related]
3. Fluorimetric determination of tauromustine (a novel antitumour agent) in formulations and biological fluids.
Walash MI; Belal F; Metwally ME; Hefnawy MM
J Pharm Biomed Anal; 1993 Aug; 11(8):777-80. PubMed ID: 8257744
[No Abstract] [Full Text] [Related]
4. The disposition of TCNU (tauromustine) in human malignant glioma: pharmacokinetic studies and clinical implications.
Whittle IR; MacPherson JS; Miller JD; Smyth JF
J Neurosurg; 1990 May; 72(5):721-5. PubMed ID: 2157825
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of tauromustine in cancer patients. Phase I studies.
Gunnarsson PO; Vibe-Petersen J; Macpherson JS; Warrington PS; Polacek J; Ellman M; Hansen HH; Smyth JF
Cancer Chemother Pharmacol; 1989; 23(3):176-80. PubMed ID: 2924375
[TBL] [Abstract][Full Text] [Related]
6. Quantitative determination of 1-2(chloroethyl)-3-(beta-D-glucopyranosyl)-1-nitrosourea in blood and urine of man.
Nakajima O; Yoshida Y; Kubota T; Takemasa Y; Koyama Y
J Chromatogr; 1982 May; 229(2):481-6. PubMed ID: 6212589
[No Abstract] [Full Text] [Related]
7. Qualitative and quantitative analysis of a new sulphur-containing nitrosourea in blood by high-performance liquid chromatography.
Labarre P; Godeneche D; Madelmont JC; Triana K; Mathe G; Veyre A
J Chromatogr; 1987 Aug; 419():381-7. PubMed ID: 3667796
[No Abstract] [Full Text] [Related]
8. High-performance liquid chromatographic analysis of felotaxel, a novel anti-cancer drug, in rat plasma and in human plasma and urine.
Yan L; YanYan J; MinChun C; Jing Y; Ying S; ChengTao L; Jie G; CaiYang L; ZhenXing Z; AiDong W; Yi D
J Chromatogr Sci; 2013 Mar; 51(3):292-6. PubMed ID: 22933511
[TBL] [Abstract][Full Text] [Related]
9. Effects of routes of administration of TCNU on its plasma, tissue and tumour concentrations.
Double JA; Bibby MC; Loadman PM; Bloomer JC
Eur J Cancer Clin Oncol; 1988 Aug; 24(8):1355-60. PubMed ID: 3181256
[TBL] [Abstract][Full Text] [Related]
10. Influence of hydralazine on the pharmacokinetics of tauromustine (TCNU) in mice.
Bibby MC; Loadman PM; al-Ghabban AF; Double JA
Br J Cancer; 1992 Mar; 65(3):347-50. PubMed ID: 1558786
[TBL] [Abstract][Full Text] [Related]
11. 5-Fluorouracil causes alterations in the pharmacokinetic profile of tauromustine in NMRI mice.
Hill SR; Bibby MC
Cancer Chemother Pharmacol; 1994; 34(1):57-62. PubMed ID: 8174203
[TBL] [Abstract][Full Text] [Related]
12. Anti-tumour, toxicological and pharmacokinetic properties of a novel taurine-based nitrosourea (TCNU).
Hartley-Asp B; Christensson PI; Gunnarsson K; Gunnarsson PO; Jensen G; Polacek J; Stamvik A
Invest New Drugs; 1988 Apr; 6(1):19-30. PubMed ID: 3410663
[TBL] [Abstract][Full Text] [Related]
13. High-performance liquid chromatographic determination of taurine in biological fluids by post-column fluorescence reaction with thiamine.
Yokoyama T; Kinoshita T
J Chromatogr; 1991 Jul; 568(1):212-8. PubMed ID: 1770098
[TBL] [Abstract][Full Text] [Related]
14. Validation study of assay method for DX-8951 and its metabolite in human plasma and urine by high-performance liquid chromatography/atmospheric pressure chemical ionization tandem mass spectrometry.
Oguma T; Konno T; Inaba A; Nakaoka M
Biomed Chromatogr; 2001 Apr; 15(2):108-15. PubMed ID: 11268051
[TBL] [Abstract][Full Text] [Related]
15. Chromosome aberrations and pharmacokinetics in patients receiving tauromustine as either a single or a repeated dose.
Hartley-Asp B; Hansson K; Vibe-Petersen J; Hansen HH; Polacek J; Ellman M; Gunnarsson PO
Cancer Chemother Pharmacol; 1996; 38(4):309-16. PubMed ID: 8674152
[TBL] [Abstract][Full Text] [Related]
16. Determination of trimethylamine, trimethylamine N-oxide, and taurine in human plasma and urine by UHPLC-MS/MS technique.
Awwad HM; Geisel J; Obeid R
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Dec; 1038():12-18. PubMed ID: 27776328
[TBL] [Abstract][Full Text] [Related]
17. Precolumn derivatization followed by liquid chromatographic separation and determination of tramiprosate in rat plasma by fluorescence detector: application to pharmacokinetics.
Rao RN; Maurya PK; Shinde DD; Khalid S
J Pharm Biomed Anal; 2011 May; 55(2):282-7. PubMed ID: 21324628
[TBL] [Abstract][Full Text] [Related]
18. Metabolism of a novel nitrosourea, tauromustine, in the rat.
Seidegård J; Grönquist L; Gunnarsson PO
Biochem Pharmacol; 1990 May; 39(9):1431-6. PubMed ID: 2334443
[TBL] [Abstract][Full Text] [Related]
19. Quantification of topotecan and its metabolite N-desmethyltopotecan in human plasma, urine and faeces by high-performance liquid chromatographic methods.
Rosing H; van Zomeren DM; Doyle E; ten Bokkel WW; Schellens JH; Bult A; Beijnen JH
J Chromatogr B Biomed Sci Appl; 1999 Apr; 727(1-2):191-203. PubMed ID: 10360438
[TBL] [Abstract][Full Text] [Related]
20. FPSE-HPLC-DAD method for the quantification of anticancer drugs in human whole blood, plasma, and urine.
Locatelli M; Tinari N; Grassadonia A; Tartaglia A; Macerola D; Piccolantonio S; Sperandio E; D'Ovidio C; Carradori S; Ulusoy HI; Furton KG; Kabir A
J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Sep; 1095():204-213. PubMed ID: 30081349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
